Display options
Cite
Lien CY, Chuang TY, Hsu CH, et al. Oral treatment with the herbal formula B307 alleviates cardiac toxicity in doxorubicin-treated mice via suppressing oxidative stress, inflammation, and apoptosis. Onco Targets Ther. 2015;8:1193-210doi: 10.2147/OTT.S82936.
Lien, C. Y., Chuang, T. Y., Hsu, C. H., Lin, C. L., Wang, S. E., Sheu, S. J., Chien, C. T., & Wu, C. H. (2015). Oral treatment with the herbal formula B307 alleviates cardiac toxicity in doxorubicin-treated mice via suppressing oxidative stress, inflammation, and apoptosis. OncoTargets and therapy, 81193-210. https://doi.org/10.2147/OTT.S82936
Lien, Chia-Ying, et al. "Oral treatment with the herbal formula B307 alleviates cardiac toxicity in doxorubicin-treated mice via suppressing oxidative stress, inflammation, and apoptosis." OncoTargets and therapy vol. 8 (2015): 1193-210. doi: https://doi.org/10.2147/OTT.S82936
Lien CY, Chuang TY, Hsu CH, Lin CL, Wang SE, Sheu SJ, Chien CT, Wu CH. Oral treatment with the herbal formula B307 alleviates cardiac toxicity in doxorubicin-treated mice via suppressing oxidative stress, inflammation, and apoptosis. Onco Targets Ther. 2015 May 26;8:1193-210. doi: 10.2147/OTT.S82936. eCollection 2015. PMID: 26060405; PMCID: PMC4454207.
Copy Download .nbib Format: NLM
Share it on

Onco Targets Ther. 2015 May 26;8:1193-210. doi: 10.2147/OTT.S82936. eCollection 2015.

Oral treatment with the herbal formula B307 alleviates cardiac toxicity in doxorubicin-treated mice via suppressing oxidative stress, inflammation, and apoptosis.

OncoTargets and therapy

Chia-Ying Lien, Tai-Yuan Chuang, Chih-Hsiang Hsu, Ching-Lung Lin, Sheue-Er Wang, Shuenn-Jyi Sheu, Chiang-Ting Chien, Chung-Hsin Wu

Affiliations

  1. Department of Athletics, National Taiwan University, Taipei, Taiwan.
  2. Department of Life Science, National Taiwan Normal University, Taipei, Taiwan.
  3. Brion Research Institute of Taiwan, New Taipei City, Taiwan.

PMID: 26060405 PMCID: PMC4454207 DOI: 10.2147/OTT.S82936

Abstract

OBJECTIVE: This study aimed to investigate whether the herbal formula B307 could alleviate doxorubicin (DOX)-induced acute cardiotoxicity. If so, we further unraveled possible molecular mechanisms of cardiac protection under treatment with the herbal formula B307.

METHODS: Before the animal experiment, we examined relative viabilities of Huh7 cancer cells under treatment with the herbal formula B307. To test whether oral treatment with the herbal formula B307 could alleviate cardiotoxicity, equal volumes of B307 (50 mg/kg) or saline (sham treatment) were administered to 20-week-old male mice once daily for 14 consecutive days. Then, DOX (10 mg/kg; ip) was administered to male mice under B307 and sham treatments at 22-23 weeks of age. Cardiac functions in these mice were assessed via echocardiography at 23-24 weeks of age. Then, expressions of oxidative stress, inflammation, and apoptosis-related proteins were examined in the heart tissue by immunohistochemistry and Western blotting at 24-25 weeks of age. Apart from this, mortality rate and body weight were measured during the experiment.

RESULTS: In vitro, the relative viabilities of Huh7 cancer cells under treatment with the herbal formula B307 had shown no obvious change at doses of 10-160 ng/mL. Furthermore, the relative viabilities of Huh7 cancer cells were significantly reduced under DOX treatment but showed no significant change under DOX only and DOX plus B307 treatment. In vivo, the mortality rate, body weight, and cardiac function of DOX-treated mice were obviously improved under oral treatment with the herbal formula B307. Furthermore, cardiac expressions of endothelial nitric oxide synthase, superoxide dismutase 2, and B-cell lymphoma 2 were significantly enhanced, but tumor necrosis factor alpha, NFKB1 (p50 and its precursor, p105), neurotrophin-3, Bcl-2-associated X protein, calpain, caspase 12, caspase 9, and caspase 3 were significantly suppressed in DOX-treated mice under oral treatment with the herbal formula B307.

CONCLUSION: Our results revealed that oral treatment with the herbal formula B307 may provide cardioprotection in DOX-treated mice via suppressing oxidative stress, inflammation, and apoptosis in heart tissue. We believe that the herbal formula B307 may be developed as a potential alternative treatment for cancer patients under DOX treatment.

Keywords: Chinese herbal formula; apoptosis; cardiac protection; doxorubicin; inflammation; mouse model; oxidative stress

References

  1. Toxicol Pathol. 2004 Sep-Oct;32(5):536-47 - PubMed
  2. Eur J Cancer. 2009 Apr;45(6):931-91 - PubMed
  3. Phytomedicine. 2007 Oct;14 (10 ):652-8 - PubMed
  4. J Pharm Pharmacol. 2012 Jun;64(6):872-81 - PubMed
  5. Trends Cell Biol. 2000 Sep;10(9):369-77 - PubMed
  6. J Ethnopharmacol. 2011 Jun 1;135(3):772-8 - PubMed
  7. Int J Cardiol. 2005 Oct 20;105(1):40-5 - PubMed
  8. Eur J Pharmacol. 2014 Apr 5;728:107-18 - PubMed
  9. Eur J Pharmacol. 2003 Jul 18;473(1):1-7 - PubMed
  10. Drug Des Devel Ther. 2015 Feb 16;9:887-900 - PubMed
  11. J Clin Oncol. 2010 May 20;28(15):2625-34 - PubMed
  12. Science. 2003 Jan 10;299(5604):214-5 - PubMed
  13. J Clin Invest. 1980 Jan;65(1):128-35 - PubMed
  14. N Engl J Med. 2005 Jun 9;352(23):2456-7 - PubMed
  15. J Lab Clin Med. 2005 Nov;146(5):299-303 - PubMed
  16. J Neural Transm Suppl. 2007;(72 ):105-12 - PubMed
  17. Clin Exp Med. 2012 Dec;12(4):233-40 - PubMed
  18. Biochim Biophys Acta. 2002 Oct 9;1588(1):94-101 - PubMed
  19. Phytother Res. 2013 Sep;27(9):1270-6 - PubMed
  20. Thromb Haemost. 2014 Nov;112(5):1051-64 - PubMed
  21. Brain Res. 2010 Oct 21;1357:19-25 - PubMed
  22. Pharmacol Rev. 2004 Jun;56(2):185-229 - PubMed
  23. J Cell Mol Med. 2007 May-Jun;11(3):509-20 - PubMed
  24. J Neurosci Res. 2009 Jul;87(9):2145-56 - PubMed
  25. J Altern Complement Med. 2009 Apr;15(4):415-21 - PubMed
  26. Arch Pharm Res. 2011 May;34(5):821-8 - PubMed
  27. J Am Coll Cardiol. 2006 Dec 5;48(11):2258-62 - PubMed
  28. Biophys Chem. 1990 Apr;35(2-3):247-57 - PubMed
  29. Mol Interv. 2007 Jun;7(3):147-56 - PubMed
  30. Cardiovasc Res. 2002 Mar;53(4):936-43 - PubMed
  31. Pharmacol Rep. 2009 Jan-Feb;61(1):154-71 - PubMed
  32. Cardiovasc Toxicol. 2009 Dec;9(4):211-27 - PubMed
  33. Appl Opt. 2014 Sep 20;53(27):G192-7 - PubMed
  34. Exp Ther Med. 2013 Sep;6(3):826-830 - PubMed

Publication Types